Work

Meta-analysis of faricimab (Vabismo) in retinal diseases: Insights from the last decade

Year: 2025

Type: review

Abstract: Faricimab (Vabismo), a bispecific antibody developed by Roche, is designed to target both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) simultaneously. This meta-analysis aims to consolidate findings from research conducted over the past decade to assess faricimab’s clinical efficacy, safety, and comparative effectiveness in treating retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). We examined clinical trials, real-world evidence, and comparative studies to provide a thorough evaluation of faricimab’s role in retinal disease management.

Source: Journal of the College of Ophthalmologists of Sri Lanka

DOI: 10.4038/jcosl.v30i1.92

Author: K. A. Salvin

Institution: University of Kelaniya

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4410508140